📣 VC round data is live. Check it out!
- Public Comps
- Darya-Varia Laboratoria
Darya-Varia Laboratoria Valuation Multiples
Discover revenue and EBITDA valuation multiples for Darya-Varia Laboratoria and similar public comparables like Aldeyra Therapeutics, Rani Therapeutics, Vistin Pharma, Biomea Fusion and more.
Darya-Varia Laboratoria Overview
About Darya-Varia Laboratoria
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, medical and dental equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics; wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory equipment, cosmetic; wholesale trade in pharmaceuticals; laboratory testing services, health support service activities, research and development, periodic inspection services, and many more activities.
Founded
1976
HQ

Employees
1.7K
Website
Financials (FY)
EV
$80M
Valuation Multiples
Start free trialDarya-Varia Laboratoria Financials
Darya-Varia Laboratoria reported last fiscal year revenue of $125M and EBITDA of $15M.
In the same fiscal year, Darya-Varia Laboratoria generated $68M in gross profit, $15M in EBITDA, and $9M in net income.
Darya-Varia Laboratoria P&L
In the most recent fiscal year, Darya-Varia Laboratoria reported revenue of $125M and EBITDA of $15M.
Darya-Varia Laboratoria is profitable as of last fiscal year, with gross margin of 54%, EBITDA margin of 12%, and net margin of 7%.
Financial data powered by Morningstar, Inc.
Darya-Varia Laboratoria Stock Performance
Darya-Varia Laboratoria has current market cap of $100M, and enterprise value of $80M.
Market Cap Evolution
Darya-Varia Laboratoria's stock price is $0.09.
Darya-Varia Laboratoria share price decreased by 6.2% in the last year.
Darya-Varia Laboratoria has an EPS (earnings per share) of $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $80M | $100M | -0.0% | -0.0% | -5.0% | -6.2% | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDarya-Varia Laboratoria Valuation Multiples
Darya-Varia Laboratoria trades at 0.6x EV/Revenue multiple, and 5.5x EV/EBITDA.
Darya-Varia Laboratoria Financial Valuation Multiples
As of June 2, 2026, Darya-Varia Laboratoria has market cap of $100M and EV of $80M.
Darya-Varia Laboratoria has a P/E ratio of 10.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Darya-Varia Laboratoria Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Darya-Varia Laboratoria Margins & Growth Rates
In the most recent fiscal year, Darya-Varia Laboratoria reported gross margin of 54%, EBITDA margin of 12%, and net margin of 7%.
Darya-Varia Laboratoria Margins
Darya-Varia Laboratoria Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Darya-Varia Laboratoria Operational KPIs
Darya-Varia Laboratoria's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Darya-Varia Laboratoria Competitors
Darya-Varia Laboratoria competitors include Aldeyra Therapeutics, Rani Therapeutics, Vistin Pharma, Biomea Fusion, Cardiff Oncology, Ryvu Therapeutics, PepGen, Verrica Pharmaceuticals, Rallybio and Cue Biopharma.
Most Darya-Varia Laboratoria public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | 5.5x | (1.6x) | - | |||
| 37.1x | 22.6x | (1.6x) | - | |||
| 2.0x | - | 7.6x | - | |||
| - | - | (0.7x) | (0.7x) | |||
| 92.9x | 123.9x | (1.1x) | - | |||
| 4.3x | 3.2x | (4.5x) | (7.2x) | |||
| - | - | 0.2x | - | |||
| 2.3x | 2.6x | (8.8x) | - | |||
This data is available for Pro users. Sign up to see all Darya-Varia Laboratoria competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Darya-Varia Laboratoria
| Who are competitors of Darya-Varia Laboratoria? | Darya-Varia Laboratoria main competitors include Aldeyra Therapeutics, Rani Therapeutics, Vistin Pharma, Biomea Fusion, Cardiff Oncology, Ryvu Therapeutics, PepGen, Verrica Pharmaceuticals, Rallybio, Cue Biopharma. |
See public comps similar to Darya-Varia Laboratoria
Lists including Darya-Varia Laboratoria
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.